Allogene Therapeutics Income Statement (2017-2026) | ALLO

Income Statement Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.04M0.05M75.65M0.04M0.06M0.03M0.03M0.03M0.02M0.02M0.02M0.02M
Operating items
Research & Development (Quarter)
52.29M58.72M53.98M60.16M57.17M63.64M75.42M80.24M62.04M45.98M54.66M52.26M50.35M44.71M44.97M50.20M40.16M31.16M28.63M32.00M
Selling, General & Administrative (Quarter)
18.78M19.00M19.96M19.90M19.51M18.90M21.00M18.88M18.52M17.04M17.22M17.27M16.09M16.33M15.52M14.99M14.28M13.74M13.77M14.09M
Other Operating Expenses (Quarter)
13.24M4.99M10.73M2.38M
Operating Expenses (Quarter)
71.07M77.72M73.94M80.05M76.68M82.54M96.42M99.12M80.56M63.02M85.13M69.53M71.43M71.77M60.49M65.19M56.82M44.90M42.40M46.09M
Operating Income (Quarter)
-71.03M-77.67M1.71M-80.01M-76.62M-82.51M-96.39M-99.09M-80.54M-63.00M-85.11M-69.50M-71.43M-71.77M-60.49M-65.19M-56.82M-44.90M-42.40M-46.09M
EBIT (Quarter)
-71.03M-77.67M1.71M-80.01M-76.62M-82.51M-96.39M-99.09M-80.54M-63.00M-85.11M-69.50M-71.43M-71.77M-60.49M-65.19M-56.82M-44.90M-42.40M-46.09M
Non-operating items
Interest & Investment Income (Quarter)
0.62M0.39M0.19M0.49M0.32M1.00M2.76M2.06M3.78M6.21M6.26M5.43M4.99M6.71M3.03M5.52M6.19M3.93M3.66M3.57M
Other Non Operating Income (Quarter)
-0.53M-0.91M-1.81M0.92M-3.99M-2.73M-3.64M2.06M-2.47M-5.50M-6.93M-0.93M0.09M-1.12M-1.95M0.09M-0.04M-0.08M0.25M0.21M
Non Operating Income (Quarter)
-0.53M-0.91M-3.33M1.41M-3.67M-2.73M-3.64M-0.88M1.31M0.71M-0.67M4.50M5.07M-1.12M18.02M5.46M5.88M3.50M0.25M3.48M
Net income details
EBT (Quarter)
-70.41M-77.28M1.89M-79.52M-76.30M-81.51M-93.64M-97.03M-76.76M-56.79M-78.84M-64.07M-66.44M-65.17M-57.54M-59.83M-50.90M-41.32M-39.06M-42.82M
Tax Provisions (Quarter)
Profit After Tax (Quarter)
-70.94M-78.19M0.09M-78.61M-80.29M-84.24M-97.28M-99.97M-79.23M-62.29M-85.78M-65.00M-66.36M-66.29M-59.94M-59.73M-50.94M-41.40M-38.81M-42.61M
Income from Continuing Operations (Quarter)
-70.41M-77.28M1.89M-79.52M-76.30M-81.51M-93.64M-97.03M-76.76M-56.79M-78.84M-64.07M-66.44M-65.17M-57.54M-59.83M-50.90M-41.32M-39.06M-42.82M
Consolidated Net Income (Quarter)
-70.41M-77.28M1.89M-79.52M-76.30M-81.51M-93.64M-97.03M-76.76M-56.79M-78.84M-64.07M-66.44M-65.17M-57.54M-59.83M-50.90M-41.32M-39.06M-42.82M
Income towards Parent Company (Quarter)
-70.41M-77.28M1.89M-79.52M-76.30M-81.51M-93.64M-97.03M-76.76M-56.79M-78.84M-64.07M-66.44M-65.17M-57.54M-59.83M-50.90M-41.32M-39.06M-42.82M
Net Income towards Common Stockholders (Quarter)
-70.41M-77.28M1.89M-79.52M-76.30M-81.51M-93.64M-97.03M-76.76M-56.79M-78.84M-64.07M-66.44M-65.17M-57.54M-59.83M-50.90M-41.32M-39.06M-42.82M
Additional items
EPS (Basic) (Quarter)
-0.53-0.570.01-0.56-0.56-0.59-0.68-0.69-0.54-0.37-0.51-0.38-0.35-0.32-0.28-0.28-0.23-0.19-0.17-0.18
EPS (Weighted Average and Diluted) (Quarter)
-0.53-0.570.01-0.56-0.56-0.59-0.68-0.69-0.54-0.37-0.51-0.38-0.35-0.32-0.28-0.28-0.23-0.19-0.17-0.18
Shares Outstanding (Weighted Average) (Quarter)
134.83M134.69M135.82M141.36M142.38M143.66M143.15M144.56M146.80M153.09M156.93M169.13M190.03M209.19M194.81M215.36M218.93M222.04M220.62M240.29M
Shares Outstanding (Diluted Average) (Quarter)
134.83M137.03M135.82M141.36M143.39M142.81M143.15M144.56M145.69M153.09M156.93M169.13M190.03M209.19M194.81M215.36M218.93M222.04M220.62M240.29M
EBITDA (Quarter)
-71.17M-78.25M-2.08M-85.29M-82.51M-85.73M-94.24M-95.98M-77.15M-60.85M-84.32M-64.97M-66.21M-65.36M-60.19M-59.60M-51.03M-41.12M-38.78M-43.06M
Interest Expenses (Quarter)
0.10M0.08M0.15M0.27M0.34M0.31M0.30M
Shares Outstanding (Quarter)
142.12M142.44M142.62M22.03M143.72M144.03M144.44M145.74M167.13M168.18M168.64M170.45M209.05M209.50M212.21M218.60M220.13M223.16M229.41M244.82M
Tax Rate (Quarter)